Nanobac Pharmaceuticals, Inc. Acquires Option to License Calgenex Corporation Technology to Treat Atherosclerosis and Prostatitis

Published: Oct 03, 2007

TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announced today that it signed an agreement with Calgenex granting Nanobac an option to assess Calgenex’ drug delivery technology for potential use with Nanobac’s drug combinations used in treating atherosclerosis, prostatitis, and other pathologic calcification diseases. The technology includes a novel combination of bisphosphonate and silicic acid.

Back to news